▁British 10.375
▁Bi 10.8359375
ote 5.5859375
ch 4.51171875
▁Pl 7.578125
c 5.90625
, 6.2421875
▁a 4.87109375
▁ren 9.4296875
owned 0.751953125
▁ph 6.4921875
arma 1.8876953125
ce 0.36376953125
ut 4.359375
ical 0.06463623046875
▁company 2.212890625
, 1.26953125
▁has 4.390625
▁recently 4.34765625
▁generated 7.09765625
▁considerable 5.80859375
▁excitement 3.390625
▁in 1.7578125
▁the 0.35107421875
▁medical 4.04296875
▁field 3.275390625
▁with 3.22265625
▁its 2.0625
▁prom 6.421875
ising 0.4072265625
▁cancer 7.83203125
▁drug 3.453125
, 2.181640625
▁Mar 8.5625
im 8.4140625
ast 8.1953125
at 5.4140625
. 2.537109375
▁Though 8.8515625
▁the 1.82421875
▁drug 2.671875
▁displays 8.203125
▁significant 4.515625
▁potential 2.501953125
, 1.015625
▁several 6.04296875
▁considerable 9.5390625
▁hur 2.8203125
d 0.0010318756103515625
les 0.0017242431640625
▁remain 1.75
▁on 5.03125
▁the 0.2744140625
▁path 1.8447265625
▁to 0.403076171875
▁block 8.4375
b 0.1734619140625
uster 0.05810546875
▁success 1.8251953125
. 0.292724609375
<0x0A> 1.0576171875
Mar 3.802734375
im 1.771484375
ast 0.0289764404296875
at 0.004169464111328125
, 1.458984375
▁an 2.576171875
▁innov 3.962890625
ative 0.040740966796875
▁matrix 10.390625
▁metal 4.765625
lo 0.061004638671875
prote 0.0792236328125
in 0.11639404296875
ase 0.00528717041015625
▁in 0.7158203125
hib 0.0002129077911376953
itor 0.005664825439453125
, 0.66845703125
▁has 1.80859375
▁shown 2.43359375
▁remarkable 2.734375
▁effic 2.689453125
acy 0.00027251243591308594
▁in 0.49853515625
▁pre 3.509765625
cl 0.2296142578125
in 3.0159950256347656e-05
ical 0.0019989013671875
▁and 3.048828125
▁early 1.951171875
- 2.29296875
stage 1.294921875
▁clin 0.2352294921875
ical 0.0013151168823242188
▁tri 0.68896484375
als 0.00030732154846191406
, 1.853515625
▁potentially 5.47265625
▁revolution 4.51171875
izing 0.02178955078125
▁cancer 1.6591796875
▁treatment 0.61669921875
. 0.6376953125
▁By 5.1171875
▁in 1.2822265625
hib 0.0029144287109375
iting 0.0006060600280761719
▁en 5.11328125
zym 0.0037384033203125
es 0.2003173828125
▁cru 6.15234375
cial 0.006587982177734375
▁for 1.2548828125
▁tum 1.611328125
or 0.029266357421875
▁growth 0.7109375
▁and 0.9189453125
▁pro 2.185546875
gression 0.2186279296875
, 0.06304931640625
▁Mar 0.67431640625
im 0.0017681121826171875
ast 0.01447296142578125
at 0.0007686614990234375
▁has 1.6787109375
▁demonstrated 2.412109375
▁an 3.953125
▁ability 1.541015625
▁to 0.01448822021484375
▁imp 6.31640625
ede 0.17138671875
▁the 1.474609375
▁spread 2.095703125
▁of 0.2083740234375
▁various 5.53125
▁cancer 2.390625
▁types 0.42578125
. 1.2216796875
▁This 3.455078125
▁break 4.1328125
through 0.00372314453125
▁has 1.9375
▁raised 4.1953125
▁hopes 1.9306640625
▁of 1.96484375
▁improved 5.02734375
▁patient 2.435546875
▁out 0.361572265625
comes 0.0027103424072265625
▁and 1.04296875
▁a 1.919921875
▁higher 4.3828125
▁quality 1.7236328125
▁of 0.022735595703125
▁life 0.0097198486328125
▁for 1.87109375
▁those 0.71337890625
▁affected 2.05859375
▁by 0.2371826171875
▁cancer 0.57763671875
. 0.1973876953125
<0x0A> 0.6005859375
Des 3.79296875
p 0.023193359375
ite 0.00010001659393310547
▁these 1.68359375
▁prom 1.1337890625
ising 0.00045943260192871094
▁results 0.91552734375
, 0.0721435546875
▁British 12.65625
▁Bi 2.90234375
ote 0.0013713836669921875
ch 0.064208984375
▁Pl 1.953125
c 0.0003147125244140625
▁faces 4.8046875
▁significant 1.8134765625
▁challeng 1.0205078125
es 0.0001304149627685547
▁in 1.076171875
▁transform 6.41015625
ing 0.00048828125
▁Mar 1.0546875
im 0.00138092041015625
ast 0.015838623046875
at 0.0007791519165039062
▁from 1.373046875
▁a 0.48388671875
▁prom 1.3662109375
ising 0.00014793872833251953
▁drug 1.390625
▁candidate 1.654296875
▁into 0.62158203125
▁a 0.1563720703125
▁world 5.51171875
- 0.193603515625
leading 2.5703125
▁block 2.58203125
b 0.0016384124755859375
uster 0.0012683868408203125
. 0.578125
▁One 3.7421875
▁of 0.71728515625
▁the 0.1387939453125
▁primary 2.20703125
▁obst 1.8486328125
acles 0.00035119056701660156
▁lies 3.787109375
▁in 0.2117919921875
▁obtain 2.98828125
ing 0.0001087188720703125
▁regul 1.369140625
atory 0.00029397010803222656
▁appro 0.10064697265625
val 2.2172927856445312e-05
. 2.380859375
▁The 2.11328125
▁drug 1.6494140625
' 1.9912109375
s 0.0003333091735839844
▁safety 3.541015625
▁profile 1.091796875
▁and 2.0390625
▁effic 1.0068359375
acy 2.2292137145996094e-05
▁data 3.8125
▁must 1.6259765625
▁with 6.6796875
stand 0.0034313201904296875
▁rig 1.783203125
orous 0.00438690185546875
▁scr 0.4833984375
ut 3.62396240234375e-05
iny 0.0011644363403320312
▁from 0.8857421875
▁regul 1.4404296875
atory 0.28955078125
▁bodies 1.326171875
▁such 2.16796875
▁as 0.003429412841796875
▁the 0.0325927734375
▁Medic 7.10546875
ines 0.01050567626953125
▁and 0.0853271484375
▁Health 0.004138946533203125
care 0.0814208984375
▁products 1.9111328125
▁Reg 0.0091094970703125
ul 0.0016946792602539062
atory 0.0007543563842773438
▁Agency 0.037261962890625
▁( 0.23193359375
M 0.0145721435546875
H 0.00226593017578125
RA 0.0001773834228515625
). 1.0361328125
▁While 4.1796875
▁pre 5.7265625
cl 0.388916015625
in 1.0251998901367188e-05
ical 0.0010471343994140625
▁tri 2.087890625
als 0.00010836124420166016
▁indicate 3.970703125
▁positive 4.05078125
▁results 0.56494140625
, 0.165771484375
▁further 4.79296875
▁clin 1.5478515625
ical 0.0010547637939453125
▁studies 2.6484375
▁involving 6.125
▁a 2.984375
▁larger 0.99755859375
▁pool 4.28515625
▁of 0.0019588470458984375
▁patients 0.34130859375
▁are 1.146484375
▁necessary 1.2841796875
. 2.97265625
▁These 3.591796875
▁tri 1.603515625
als 1.2874603271484375e-05
▁can 4.08203125
▁be 2.3125
▁cost 2.43359375
ly 0.01174163818359375
▁and 0.385986328125
▁time 0.51611328125
- 0.2099609375
consum 0.039581298828125
ing 1.33514404296875e-05
, 0.305908203125
▁which 2.49609375
▁may 1.810546875
▁h 2.33203125
inder 0.0020542144775390625
▁the 0.8515625
▁drug 1.2802734375
' 0.052886962890625
s 0.00011646747589111328
▁progress 3.345703125
▁towards 2.48046875
▁regul 1.4052734375
atory 0.0011034011840820312
▁appro 0.0213623046875
val 5.5909156799316406e-05
. 0.0760498046875
<0x0A> 0.50146484375
F 2.85546875
ur 0.024169921875
ther 4.673004150390625e-05
more 0.427978515625
, 0.0001666545867919922
▁competition 6.4453125
▁within 3.349609375
▁the 0.0283203125
▁ph 1.44140625
arma 0.00036263465881347656
ce 0.0027675628662109375
ut 1.6689300537109375e-06
ical 5.030632019042969e-05
▁industry 0.1348876953125
▁pos 3.927734375
es 0.0002543926239013672
▁a 0.432861328125
▁form 5.75
id 0.0003528594970703125
able 4.315376281738281e-05
▁hur 3.955078125
d 1.537799835205078e-05
le 0.00010824203491210938
. 1.4169921875
▁Several 4.0625
▁established 3.96875
▁players 2.8984375
, 2.208984375
▁armed 11.2421875
▁with 0.0008397102355957031
▁their 4.7421875
▁own 0.8505859375
▁cutting 5.2734375
- 0.0038166046142578125
edge 0.0005998611450195312
▁cancer 2.130859375
▁treat 1.3544921875
ments 1.4424324035644531e-05
, 0.07318115234375
▁are 0.79052734375
▁v 2.568359375
ying 0.0006170272827148438
▁for 0.11138916015625
▁domin 4.7265625
ance 0.0019969940185546875
▁in 0.52294921875
▁the 0.18212890625
▁market 1.0
. 0.1865234375
▁British 2.4453125
▁Bi 0.0023822784423828125
ote 3.6716461181640625e-05
ch 0.013702392578125
▁Pl 0.04058837890625
c 0.0006976127624511719
▁must 0.55078125
▁navigate 3.591796875
▁through 2.234375
▁this 0.87353515625
▁compet 2.134765625
itive 0.0006642341613769531
▁landscape 0.282470703125
, 3.048828125
▁distingu 6.0078125
ishing 0.0004448890686035156
▁Mar 3.689453125
im 0.0005431175231933594
ast 0.00806427001953125
at 0.0003204345703125
' 4.3984375
s 6.747245788574219e-05
▁unique 1.025390625
▁s 3.85546875
elling 0.00013697147369384766
▁proposition 0.85888671875
▁and 1.24609375
▁establish 3.03125
ing 0.031036376953125
▁its 1.158203125
▁superior 4.8125
ity 0.280029296875
▁over 0.330322265625
▁existing 1.556640625
▁alternatives 2.962890625
. 0.03021240234375
▁This 2.044921875
▁requires 1.6318359375
▁substantial 5.48828125
▁invest 0.69580078125
ments 1.328125
▁in 0.16845703125
▁market 2.328125
ing 0.0272369384765625
, 1.478515625
▁clin 4.08984375
ical 0.0015192031860351562
▁tri 0.280029296875
als 9.953975677490234e-05
, 0.04803466796875
▁and 0.048919677734375
▁infrastr 3.6484375
ucture 0.037506103515625
▁to 2.44140625
▁effectively 5.22265625
▁promote 2.123046875
▁and 1.7490234375
▁dist 1.03515625
ribute 3.802776336669922e-05
▁the 0.190185546875
▁drug 0.0755615234375
. 0.249267578125
<0x0A> 0.39794921875
Add 3.9375
itionally 0.024871826171875
, 0.0004165172576904297
▁financial 5.77734375
▁consider 3.44140625
ations 1.2516975402832031e-05
▁represent 5.609375
▁another 1.873046875
▁challenge 2.58984375
▁for 0.96240234375
▁British 0.2083740234375
▁Bi 0.0010652542114257812
ote 6.866455078125e-05
ch 0.004299163818359375
▁Pl 0.0282135009765625
c 0.0001729726791381836
. 0.054290771484375
▁The 1.0947265625
▁costs 5.03515625
▁associated 0.59912109375
▁with 0.0004963874816894531
▁clin 2.17578125
ical 0.0002301931381225586
▁tri 0.132568359375
als 1.5616416931152344e-05
, 0.9072265625
▁manufact 2.390625
uring 0.0044708251953125
, 0.2042236328125
▁market 3.224609375
ing 0.004119873046875
, 0.0271759033203125
▁and 0.0689697265625
▁obtain 9.703125
ing 9.834766387939453e-05
▁regul 0.034393310546875
atory 3.3974647521972656e-05
▁appro 0.0219268798828125
val 3.123283386230469e-05
s 2.544921875
▁demand 7.30078125
▁substantial 1.47265625
▁fund 2.63671875
ing 0.00045490264892578125
. 0.2322998046875
▁In 2.537109375
vest 1.5
ments 2.388671875
▁must 1.3779296875
▁be 0.25146484375
▁secured 4.6796875
▁to 0.58544921875
▁meet 4.140625
▁these 0.34912109375
▁dem 3.16796875
ands 1.9073486328125e-05
, 0.7109375
▁either 5.734375
▁through 0.3720703125
▁partners 4.3125
hips 0.100830078125
, 2.65625
▁lic 3.623046875
ens 0.0648193359375
ing 0.00040149688720703125
▁agre 0.56201171875
ements 1.5497207641601562e-06
, 0.00995635986328125
▁or 0.13427734375
▁other 2.83203125
▁financial 2.544921875
▁arrang 0.49951171875
ements 1.9431114196777344e-05
. 0.05865478515625
▁Sec 6.22265625
uring 0.004669189453125
▁sufficient 2.52734375
▁fund 0.5537109375
ing 0.00010526180267333984
▁is 1.1103515625
▁essential 1.697265625
▁to 0.71142578125
▁sust 3.837890625
ain 1.1083984375
▁the 0.94091796875
▁drug 2.384765625
' 0.05865478515625
s 7.021427154541016e-05
▁development 0.73876953125
▁and 0.358642578125
▁reach 4.609375
▁the 1.8037109375
▁market 0.6328125
▁effectively 6.2109375
. 0.13623046875
<0x0A> 0.216552734375
Des 1.8896484375
p 0.001216888427734375
ite 0.00012123584747314453
▁these 0.38818359375
▁hur 2.541015625
d 2.384185791015625e-06
les 0.00010275840759277344
, 0.02154541015625
▁British 0.07525634765625
▁Bi 0.0009140968322753906
ote 4.3511390686035156e-05
ch 0.00441741943359375
▁Pl 0.0078125
c 0.00011658668518066406
▁remains 2.51953125
▁optim 0.501953125
istic 0.00012981891632080078
▁about 0.1878662109375
▁Mar 1.541015625
im 0.00026679039001464844
ast 0.004383087158203125
at 0.0007772445678710938
' 0.0279998779296875
s 0.00023925304412841797
▁future 1.4853515625
▁potential 2.94921875
. 0.226318359375
▁The 0.489013671875
▁company 1.29296875
' 1.8134765625
s 0.0001939535140991211
▁commit 3.2578125
ment 0.0006136894226074219
▁to 0.059326171875
▁research 1.3857421875
▁and 0.128662109375
▁development 0.0523681640625
, 0.76611328125
▁couple 1.048828125
d 6.866455078125e-05
▁with 0.0005660057067871094
▁early 6.8515625
▁positive 6.015625
▁indic 3.21875
ations 0.0704345703125
, 2.1640625
▁fost 6.51171875
ers 0.93701171875
▁hope 1.5078125
▁for 0.6982421875
▁a 1.0078125
▁successful 1.9462890625
▁outcome 1.98828125
. 0.1949462890625
▁However 3.47265625
, 0.00027632713317871094
▁a 4.1796875
▁considerable 6.51171875
▁amount 0.456298828125
▁of 0.018280029296875
▁time 1.7958984375
, 1.7958984375
▁dedic 5.015625
ation 2.4318695068359375e-05
, 0.0256500244140625
▁and 0.0140838623046875
▁resources 1.5205078125
▁will 1.564453125
▁determine 11.0
▁Mar 2.4765625
im 0.0003886222839355469
ast 0.0056610107421875
at 0.0007205009460449219
' 0.002788543701171875
s 5.745887756347656e-05
▁journey 5.47265625
▁from 3.1484375
▁an 3.248046875
▁exc 3.205078125
iting 7.736682891845703e-05
▁prospect 4.0390625
▁to 0.0555419921875
▁a 0.11083984375
▁break 4.203125
through 0.0076141357421875
▁block 2.07421875
b 0.00017940998077392578
uster 0.0002313852310180664
▁drug 2.4140625
. 0.0222930908203125
<0x0A> 0.322265625
In 3.69140625
▁conclusion 1.2861328125
, 0.003330230712890625
▁British 0.353515625
▁Bi 0.00266265869140625
ote 4.172325134277344e-05
ch 0.006488800048828125
▁Pl 0.019775390625
c 0.00021886825561523438
' 3.064453125
s 0.00023281574249267578
▁cancer 6.60546875
▁drug 0.3759765625
▁Mar 1.3916015625
im 0.00021898746490478516
ast 0.0024967193603515625
at 0.00016939640045166016
▁has 0.61474609375
▁shown 1.7705078125
▁trem 2.958984375
end 2.2411346435546875e-05
ous 0.0006976127624511719
▁promise 0.1917724609375
▁in 0.304931640625
▁early 2.953125
▁tri 3.251953125
als 6.663799285888672e-05
. 0.7626953125
▁However 1.5615234375
, 0.0002579689025878906
▁regul 3.326171875
atory 0.003589630126953125
▁appro 0.486572265625
val 5.9485435485839844e-05
, 1.9384765625
▁the 4.77734375
▁compet 4.73828125
itive 0.0036525726318359375
▁landscape 0.240234375
, 0.5791015625
▁and 0.1171875
▁the 3.693359375
▁need 2.66015625
▁for 0.057830810546875
▁substantial 1.0595703125
▁fund 0.5302734375
ing 0.0005526542663574219
▁are 2.111328125
▁significant 1.501953125
▁obst 1.484375
acles 4.184246063232422e-05
▁that 0.79736328125
▁must 0.249267578125
▁be 0.0011005401611328125
▁overcome 0.09326171875
▁to 1.2919921875
▁bring 2.38671875
▁Mar 1.9638671875
im 0.00024044513702392578
ast 0.0022220611572265625
at 0.0001538991928100586
▁to 0.03143310546875
▁market 0.7548828125
▁successfully 2.6328125
. 0.02349853515625
▁The 1.8916015625
▁journey 6.91796875
▁to 1.6435546875
▁becoming 4.09375
▁a 0.06390380859375
▁block 1.1669921875
b 7.104873657226562e-05
uster 0.00041556358337402344
▁drug 0.2998046875
▁may 2.90234375
▁be 0.3388671875
▁challeng 2.412109375
ing 0.0002332925796508789
, 0.0953369140625
▁but 0.01216888427734375
▁the 1.6513671875
▁potential 1.3896484375
▁benefits 2.486328125
▁for 1.9150390625
▁cancer 1.8212890625
▁patients 0.0296478271484375
▁make 1.939453125
▁it 0.751953125
▁a 3.7890625
▁journey 9.3203125
▁worth 0.09075927734375
▁purs 0.9140625
uing 0.0006508827209472656
. 0.02679443359375
